Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Total Non-Current Liabilities (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Total Non-Current Liabilities for 9 consecutive years, with -$34.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 113.01% to -$34.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$34.4 million, a 113.01% decrease, with the full-year FY2025 number at -$34.4 million, down 113.01% from a year prior.
  • Total Non-Current Liabilities was -$34.4 million for Q4 2025 at Akebia Therapeutics, up from -$46.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $453.5 million in Q4 2021 to a low of -$46.6 million in Q3 2025.
  • A 5-year average of $258.1 million and a median of $274.0 million in 2023 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: rose 20.73% in 2022, then tumbled 227.14% in 2025.
  • Akebia Therapeutics' Total Non-Current Liabilities stood at $453.5 million in 2021, then decreased by 22.81% to $350.1 million in 2022, then dropped by 24.76% to $263.4 million in 2023, then grew by 0.48% to $264.7 million in 2024, then tumbled by 113.01% to -$34.4 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Total Non-Current Liabilities are -$34.4 million (Q4 2025), -$46.6 million (Q3 2025), and -$34.6 million (Q2 2025).